Non-screened Breast Cancer Patients More Likely to Receive Chemo

Share this content:
Non-screened Breast Cancer Patients More Likely to Receive Chemo
Non-screened Breast Cancer Patients More Likely to Receive Chemo

(HealthDay News) -- Middle-aged breast cancer patients undergoing screening mammography are statistically less likely to be treated with chemotherapy compared to non-screened patients, according to a study presented at the annual meeting of the American Roentgen Ray Society, held from May 4 to 9 in San Diego.

Nelly Salem, MD, from University Hospitals-Case Western Reserve in Cleveland, and colleagues compared the use of chemotherapy for treatment of breast cancer in women ages 40 to 49 undergoing screening mammography (screened; 149 patients) compared to women diagnosed after diagnostic evaluation (non-screened; 81 patients).

RELATED: Breast Cancer Resource Center

The researchers found that, of the 230 primary breast cancers, non-screened patients were more likely to undergo chemotherapy (P = 0.042) than screened patients. The majority of the 98 high-risk lesions identified (81%) were diagnosed in the screened population.

"When the U.S. Preventive Services Task Force guidelines were published in 2009, confusion was created among patients and primary care providers on when and if 40- to 49-year-old women should be screened," Salem said in a statement. "Without screening mammography, these asymptomatic high-risk women would be unaware of their risk and the opportunity to decrease their risk of subsequent breast cancer development with use of chemoprevention."


  1. Salem N, Kremer M, Lyons J, et al. Abstract 050: Neglecting to Screen Women Aged 40–49 With Mammography: What Is the Impact on Breast Cancer Treatment and Potential Risk Reduction? Presented at: ARRS Annual Meeting 2014; May 4-9, 2014; San Diego.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs